Efatutazone
- Generic Name
- Efatutazone
- Drug Type
- Small Molecule
- Chemical Formula
- C27H26N4O4S
- CAS Number
- 223132-37-4
- Unique Ingredient Identifier
- M17ILL71MC
- Background
Efatutazone has been used in trials studying the treatment of Lymphoma, Liposarcoma, Solid Tumors, Multiple Myeloma, and Recurrent Thyroid Cancer, among others.
Efatutazone Dihydrochloride in Treating Patients With Previously Treated Myxoid Liposarcoma That Cannot Be Removed by Surgery
- First Posted Date
- 2014-09-26
- Last Posted Date
- 2025-01-27
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 15
- Registration Number
- NCT02249949
- Locations
- 🇺🇸
Northside Hospital, Atlanta, Georgia, United States
🇺🇸Rush - Copley Medical Center, Aurora, Illinois, United States
🇺🇸Illinois CancerCare-Canton, Canton, Illinois, United States
Inolitazone Dihydrochloride and Paclitaxel in Treating Patients With Advanced Anaplastic Thyroid Cancer
Phase 2
Completed
- Conditions
- Anaplastic Thyroid CancerRecurrent Thyroid Cancer
- Interventions
- First Posted Date
- 2014-06-02
- Last Posted Date
- 2025-01-27
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 19
- Registration Number
- NCT02152137
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸Minor and James Medical PLLC, Seattle, Washington, United States
🇺🇸Swedish Medical Center-Cherry Hill, Seattle, Washington, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath